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Disease-free survival at 2 and 3 years 
is a significant early surrogate 
marker predicting the 5-year overall 
survival in patients treated with 
radical cystectomy for urothelial 
carcinoma of the bladder: external 
evaluation and validation in a cohort 
of Korean patients
Hyung Suk Kim , Chang Wook Jeong , Cheol Kwak , Hyeon Hoe Kim and Ja Hyeon Ku*
Department of Urology, Seoul National University College of Medicine, Seoul, South Korea
Purpose: We aimed to externally validate the association of 2- and 3-year disease-free 
survival (DFS) with 5-year overall survival (OS) in patients treated with radical cystectomy 
(RC) for urothelial carcinoma (UC) of the bladder.
Materials and Methods: We reviewed the clinical data of 422 patients who underwent 
RC for UC of the bladder in our institution between 1991 and 2012. Survival curves were 
plotted with the Kaplan–Meier method. The Kappa statistic and Kendall tau-b test were 
used to assess the agreements between 2- and 3-year DFS and 5-year OS.
results: In the entire study population, 2- and 3-year DFS and 5-year OS rates were 
76.4, 71.5, and 67.4%, respectively. All Kappa and Kendall’s tau-b test values for agree-
ments between 2- and 3-year DFS and 5-year OS were more than 0.40, indicating 
moderate agreement for all patients and in each patient subgroup selected according 
to specific variables (all p-values <0.05). Kaplan–Meier analysis for DFS and Cox-
proportional hazard models for landmark analysis at each time point indicated that most 
recurrences occurred within 3 years after surgery. The 5-year OS rates of patients who 
were recurrence-free at each time point gradually increased to more than 95% in an 
extended recurrence-free interval of 12–36 months.
conclusion: Our external validation results support the existing finding that 2- and 
3-year DFS can be a valid early surrogate end point to predict 5-year OS after RC in 
patients with UC of the bladder.
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inTrODUcTiOn
Urothelial carcinoma (UC) of the bladder is a heterogene-
ous malignant disease with a variable clinical course and 
presentation (1). According to current guidelines, radical 
cystectomy (RC) with pelvic lymph node dissection (PLND) 
is the primary treatment option for muscle-invasive disease, 
which accounts for approximately 30% at initial diagnosis, 
and several high-risk non-muscle-invasive diseases, such as 
those refractory to bacillus Calmette–Guérin (BCG) therapy, 
histological variants of UC (i.e., micropapillary), and pT1 
high-grade tumor with carcinoma in situ (CIS) (2–4). However, 
both the risk for undetectable occult micro-metastasis and 
tumor recurrence rates of 30–60% within 5  years after RC 
suggest that a unimodal treatment of RC may be insufficient 
for complete tumor control (1). Therefore, a multimodal 
approach, including neoadjuvant or adjuvant chemotherapy, 
should be considered for patients at high risk of postoperative 
recurrence (5).
Many studies address the impact of neoadjuvant or adjuvant 
chemotherapy on survival outcomes in UC of the bladder (5–7). 
While evidence from several meta-analyses exists for the use of 
neoadjuvant chemotherapy (cisplatin-based) in UC of the blad-
der (8, 9), data supporting adjuvant chemotherapy are suboptimal 
because of conflicting results (6, 7). Regardless of cancer treat-
ment type, the goal of cancer treatment is to improve survival. 
Overall survival (OS) is widely used as the gold standard primary 
end point of clinical outcome in clinical trials for oncologic treat-
ments, including surgery or systemic chemotherapy (10). The 
limitation of OS is the required long-term follow-up duration of 
>5  years. Therefore, investigators have sought to identify early 
surrogate markers that accurately predict OS following treatment 
(10–12). Previous reports suggest that disease-free survival (DFS) 
at 2 and 3 years (2- and 3-year DFS) represents an early surrogate 
end point that can replace or predict OS after surgical intervention 
or systemic chemotherapy in various malignancies, including UC 
(13–17). Because a majority of recurrences or metastases after RC 
generally occur within 3 years (18), it is probable that decrease 
in the disease-recurrence risk within 3 years following RC may 
improve the OS. According to this hypothesis, the use of the 
2- and 3-year DFS as an early surrogate marker will facilitate the 
development of effective adjuvant chemotherapeutic regimens 
for RC.
In this study, we aimed to externally validate existing results 
(14, 15) that support the use of the 2- and 3-year DFS as a signifi-
cant early surrogate end point for predicting 5-year OS following 
RC and PLND in patients with UC of the bladder.
MaTerials anD MeThODs
study Population
After obtaining institutional review board (IRB) approval from 
Seoul National University Hospital, we retrospectively reviewed 
the records of 486 patients in the bladder cancer database who 
received RC and PLND at our institution between 1991 and 2012. 
Patients who received postoperative radiation therapy (1 patient) 
and neoadjuvant chemotherapy (50 patients), and those with 
non-UC (13 patients) were excluded from this study. Ultimately, 
a total of 422 patients were eligible for our study.
Data acquisition and Definition of 
Variables
The indications for RC and PLND included muscle-invasive 
disease exceeding clinical stage T2 or those at high risk of non-
muscle-invasive disease unresponsive to intravesical therapy 
(i.e., BCG instillation), such as high-grade Ta or T1 tumors 
and CIS. RC and PLND were performed as previously reported 
(19). Pathological specimens obtained from RC and PLND were 
examined by a professional genitourinary pathologist. Assessed 
pathological variables included pathological tumor (pT) stage 
and tumor grade, pathological nodal (pN) stage, perivesical mar-
gin, total number of removed lymph nodes and positive lymph 
nodes, and presence of CIS, lymphovascular invasion (LVI), and 
variant histology. Pathological staging and grade were determined 
according to the 7th (2010) edition of the Tumor-Node-Metastasis 
classification and the 2004 World Health Organization system, 
respectively. We re-investigated the pathological stage and grade 
of patients who underwent RC prior to current guideline systems. 
Perivesical margin was defined as the presence of residual tumor 
at the area of soft tissue on the final pathological slide of the RC 
specimen; therefore, urethral and/or ureteral margin status was 
not regarded as a margin. Other evaluated covariates were age, 
sex, body mass index (BMI), and adjuvant chemotherapy history.
Follow-up
Postoperative follow-up was carried out according to institu-
tional protocol. Follow-up occurred at least every 3–4 months 
for the first year, semiannually for the second year, and annually 
thereafter. Follow-up examinations included physical examina-
tion, blood test, chest roentgenography, kidney ultrasonography, 
and/or abdomen-pelvic computed tomography. A bone scan was 
performed only in cases with bone-related symptoms. DFS was 
defined as the interval between RC and disease recurrence or 
death from any causes. Post-RC recurrence at the ureter and/or 
urethra was not considered disease recurrence, but an additional 
primary event. The duration of OS was estimated from the date 
of RC to the date of last follow-up or death from any cause. 
Living patients were censored from relevant analyses. Death 
was identified by reviewing medical charts and/or from the 
annual census of the Korea National Statistical Office. Cause of 
death was determined by the responsible physicians and death 
certificates.
statistical analysis
Continuous and categorical variables were, respectively, 
expressed as the median and interquartile range (IQR) and abso-
lute numbers and relative percentages (%) in accordance with 
descriptive and frequency analyses. DFS and OS were estimated 
using the Kaplan–Meier method for the entire study cohort or 
subgroup stratified according to pT stage (pT2 or less versus pT3 
or greater), and then compared using univariate log-rank tests 
between groups. We applied the Kappa statistic and Kendall’s 
tau-b test (20), which measure agreement between categorical 
TaBle 1 | Baseline characteristics of the study cohort.
Variables
No. of patients 422
Age (year), median(IQR) 64.0 (57.5–70.0)
≤65 years 224 (53.1%)
>65 years 198 (46.9%)
Gender, n (%)
Male 365 (86.5%)
Female 57 (13.5%)
BMI (kg/m2), median (IQR) 23.3 (21.2–25.1)
<25 310 (73.5%)
≥25 112 (26.5%)
Tumor grade, n (%)
Absence of cancer 50 (11.8%)
Low grade 20 (4.7%)
High grade 352 (83.4%)
Pathological T stage, n (%)
pT0 50 (11.8%)
pTis 36 (8.5%)
pTa 21 (5.0%)
pT1 77 (18.2%)
pT2 87 (20.6%)
pT3 122 (28.9%)
PT4 29 (7.9%)
Pathological N stage, n (%)
pN0 332 (78.7%)
pN1 37 (8.8%)
pN2 44 (10.4%)
pN3 9 (2.1%)
Presence of LVI, n (%)
Absent 277 (65.6%)
Present 145 (34.4%)
Concomitant CIS at cystectomy, n (%)
Absent 300 (71.1%)
Present 122 (28.9%)
Histological variant, n (%)
No 389 (92.2%)
Yes 33 (7.8%)
Margin status, n (%)
Negative 411 (97.4%)
Positive 11 (2.6%)
Adjuvant chemotherapy, n (%)
No 320 (72.8%)
Yes 102 (24.2%)
BMI, body mass index; LVI, lymphovascular invasion; CIS, carcinoma in situ.
October 2015 | Volume 5 | Article 2463
Kim et al. DFS as surrogate marker in the bladder cancer
Frontiers in Oncology | www.frontiersin.org
variables, to elucidate the association of 2- and 3-year DFS with 
5-year OS in all patients. In addition, correlation between the 
2- and 3-year DFS and 5-year OS was evaluated at the individual 
level using Kappa statistics and the Cox-proportional hazard 
model. All statistical analyses were performed using the SPSS 
software version 21.0 (SPSS Inc., Chicago, IL, USA) and two-
sided p-values <0.05 were considered statistically significant.
resUlTs
Patient characteristics and Outcomes 
after rc
Median age and BMI of all patients were 64.0  years (IQR: 
57.5–70.0) and 23.3  kg/m2 (IQR: 21.2–25.1), respectively. The 
majority of patients were men (86.5%). There were 271 patients 
(64.2%) with pT2 or less and 151 patients (35.8%) with pT3 or 
greater disease. Adjuvant chemotherapy was administered in 102 
patients (24.2%). Other clinicopathological characteristics are 
listed in Table 1.
The respective 2- and 3-year DFS and 5-year OS were as fol-
lows: 76.4, 71.5, and 67.4% in all patients; 85.9, 80.3, and 78.6% 
in patients with pT2 or less disease; and 56.4, 52.8, and 45.4% in 
patients with pT3 or greater disease (Figure 1). The recurrence 
rates within 2 and 3 years and the 5-year OS rates after RC were 
statistically significantly different between the two groups (all 
p–values <0.001).
In the entire study population, there were 133 cases of dis-
ease recurrence with a median follow-up time of 37.3  months 
(IQR: 13.8–81.8). Among all recurrences, 91 cases (68.4%) 
occurred within the first 2  years and 107 cases (80.4%) within 
the first 3 years following RC. Among patients with pT2 or less 
disease (n = 271), there were a total of 63 recurrences (23.2%) 
with a median follow-up time of 44  months (IQR: 24.4–87.0). 
In this group of recurrences, 35 cases (55.5%) occurred within 
the first 2  years and 47 cases (74.6%) within 3  years after RC. 
For patients with pT3 or greater disease (n = 151), there were a 
total of 70 recurrences (46.4%) with a median follow-up time of 
14.9 months (IQR: 6.0–61.7). Among this group of recurrences, 
56 cases (77.1%) occurred within the first 2 years and 60 cases 
(85.7%) occurred within 3 years after RC.
Kaplan–Meier analysis with the log-rank test was used to 
analyze OS according to disease-recurrence status at 2 and 3 years 
following RC. For all patient groups including the entire study 
population, pT2 or less, and pT3 or greater, there were significant 
differences in OS rates according to time following RC (all p–val-
ues <0.001; Figure 2).
association of 2- and 3-year DFs  
and 5-year Os
The Kappa statistic and Kendall tau-b test were used to assess 
the agreements between 2- and 3-year DFS and 5-year OS. The 
statistical analysis determined values over 0.40 in each subgroup, 
in addition to the entire study population, implying at least 
moderate agreements for all relationships (all p-values <0.05; 
Table 2). In particular, substantial agreements (>0.60) between 
2- and 3-year DFS and 5-year OS in the subgroup of patients 
that included men >65  years old and the presence of variant 
histology, absence of CIS, and use of adjuvant chemotherapy 
were observed.
Overall survival was compared in a landmark analysis that 
included a total of 64, 74, 76, 85, 91, 97, 99, 104, and 107 patients, 
who presented disease recurrence at postoperative 12, 15, 18, 21, 
24, 27, 30, and 36 months, respectively. The hazard ratio (HR) 
between OS in patients with disease recurrence and those without 
recurrence at each time point is described in Figure 3. The HR 
gradually declined according to the extended disease-free inter-
val and reached the lowest level at 36 months for the entire study 
population and the pT3 or greater disease group (Figures 3A–C). 
The lowest HR level was reached at 33 months in patients with pT2 
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or less disease (Figure 3B). These results and the 2- and 3-year 
DFS and 5-year OS curves (Figure 3 and Figure 1) indicated that 
most recurrences after RC could be accurately detected within an 
observational period of approximately 36 months.
We also estimated the 5-year OS rates of patients who had no 
disease recurrence at each time point. In the entire study popula-
tion, the 5-year OS rates of patients who were disease free at each 
time point (3-month interval from 12 to 36 months) gradually 
increased from 85% at 12 months to more than 95% at 36 months, 
depending on the extended recurrence-free interval (Figure 4A). 
Twenty-four months after RC, the 5-year OS rate exceeded 90%. 
When the entire population was dichotomized according to 
tumor stage (pT2 or less vs. pT3 or greater), the trend remained 
the same in each group (Figure 4B–C).
DiscUssiOn
Overall survival is used in a variety of oncologic clinical trials 
as the primary end point to reflect the long-term efficacy and 
FigUre 1 | Overall survival and disease-free survival. (a) All patients. (B) Patients with pT2 or less disease. (c) Patients with pT3 or greater disease. Vertical 
bar represents 60 months.
outcomes for surgical intervention, radiation therapy, and system-
atic drug treatment, including neoadjuvant and adjuvant chemo-
therapy, because of several associated advantages that include ease 
of measurement and interpretation, and its clinical significance 
(10). However, this end point may be a problem for prospective 
clinical trials assessing new anti-cancer agents because of the long 
waiting periods of ≥5 years to identify treatment-related efficacy. 
Therefore, early surrogates for the OS end point, which could be 
achieved more quickly, less invasively, and in a less costly manner 
than OS, are under investigation in a number of oncologic areas, 
including urologic malignancy (11–17, 21, 22).
Because most recurrences and disease progressions occur 
within the first 2 or 3 years after cancer treatment (15, 17, 18), 
2- and 3-year DFS has been suggested as a valid predictor of 
5-year OS. For example, a pooled analysis of phase III adjuvant 
colon cancer studies including 20,898 patients across 18 ran-
domized trials revealed a high correlation between DFS and 
OS (13). This analysis led to the conclusion that DFS at the 
2- and 3-year median follow-up should replace 5-year OS as 
FigUre 2 | Overall survival by disease status. (a) Overall survival of all patients by 2-year disease status. (B) Overall survival of patients with pT2 or less disease 
by 2-year disease status. (c) Overall survival of patients with pT3 or greater disease by 2-year disease status. (D) Overall survival of all patients by 3-year disease 
status. (e) Overall survival of patients with pT2 or less disease by 3-year disease status. (F) Overall survival of patients with pT3 or greater disease by 3-year disease 
status.
TaBle 2 | The Kappa statistic and Kendall tau-b test for the dependence between disease-free survival and overall survival.
Kappa statistics (se) Kendall Tau-b (se)
2-year DFs/5-year Os 3-year DFs/5-year Os 2-year DFs/5-year Os 3-year DFs/5-year Os
Total 0.59 (0.045) 0.62 (0.043) 0.60 (0.044) 0.63 (0.043)
Age ≤65 years 0.58 (0.069) 0.63 (0.063) 0.58 (0.068) 0.63 (0.063)
Age >65 years 0.60 (0.061) 0.61 (0.060) 0.61 (0.059) 0.61 (0.060)
Male 0.60 (0.047) 0.63 (0.046) 0.61 (0.046) 0.63 (0.045)
Female 0.51 (0.142) 0.53 (0.135) 0.51 (0.142) 0.54 (0.135)
BMI <25 kg/m2 0.57 (0.052) 0.61 (0.051) 0.59 (0.051) 0.61 (0.050)
BMI ≥25 kg/m2 0.66 (0.087) 0.68 (0.082) 0.66 (0.087) 0.68 (0.082)
pT2 or less 0.54 (0.072) 0.59 (0.066) 0.55 (0.072) 0.59 (0.066)
pT3 or more 0.56 (0.066) 0.59 (0.065) 0.57 (0.064) 0.60 (0.064)
LN negative 0.54 (0.060) 0.56 (0.058) 0.55 (0.058) 0.56 (0.058)
LN positive 0.55 (0.138) 0.73 (0.113) 0.56 (0.134) 0.73 (0.113)
Histological variant (−) 0.58 (0.049) 0.62 (0.046) 0.59 (0.048) 0.62 (0.046)
Histological variant (+) 0.64 (0.130) 0.64 (0.130) 0.66 (0.121) 0.66 (0.121)
LVI (−) 0.54 (0.069) 0.60 (0.063) 0.55 (0.067) 0.60 (0.063)
LVI (+) 0.58 (0.068) 0.58 (0.068) 0.59 (0.067) 0.58 (0.068)
CIS (−) 0.63 (0.050) 0.66 (0.048) 0.64 (0.048) 0.66 (0.047)
CIS (+) 0.45 (0.104) 0.50 (0.097) 0.45 (0.104) 0.50 (0.097)
ACH (−) 0.54 (0.057) 0.57 (0.055) 0.56 (0.055) 0.57 (0.054)
ACH (+) 0.68 (0.076) 0.73 (0.070) 0.68 (0.075) 0.73 (0.070)
All p-values for Kappa statistics and Kendall Tau-b are <0.05.
LN, lymph node; LVI, lymphovascular invasion; CIS, carcinoma in situ; ACH, adjuvant chemotherapy.
October 2015 | Volume 5 | Article 2465
Kim et al. DFS as surrogate marker in the bladder cancer
Frontiers in Oncology | www.frontiersin.org
the primary end point in future colon adjuvant trials. Akamatsu 
et  al. demonstrated that progression-free survival at 2  years 
could be a reliable surrogate end point for 5-year OS in 159 
patients treated with chemoradiotherapy for locally advanced 
non-small cell lung cancer (17). These associations between 2- 
and 3-year DFS and 5-year OS have also been reported in UC 
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of the urinary tract. Sonpavde et al. evaluated the correlation of 
2- and 3-year DFS with 2- and 3-year OS in a multicenter study, 
consisting of 2,724 patients treated with RC for muscle-invasive 
bladder cancer (14). They concluded that 2- and 3-year DFS is a 
potential intermediate surrogate for 5-year OS. This group also 
reported a similar significant association for 2,492 patients with 
upper tract UC who underwent radical nephroureterectomy 
(16). In each study discussed, the authors internally validated 
their findings using only the leave-one-out method. Nuhn et al. 
completed the first external validation of correlation between 
2- and 3-year DFS and 5-year OS in patients with bladder 
cancer (15).
The results of our external validation study confirmed sig-
nificant correlations between 2- and 3-year DFS and 5-year OS. 
When performing subgroup analysis according to a specific vari-
able, the strength of this correlation was consistently maintained, 
especially in patients who received adjuvant chemotherapy. The 
association between 2- and 3-year DFS and 5-year OS in these 
patients showed substantial agreements with values >0.60. 
Similar to previous studies (14, 16, 17), most recurrences (more 
than 80%) occurred within the first 3  years after RC. Besides, 
in our study, the 5-year OS rates in patients without recurrence 
gradually increased at each time point in accordance with the 
extended disease-free interval. Patients with a disease-free inter-
val >24 months showed a 5-year OS rate of >90%. According to 
our findings, DFS at 2 and 3 years may function as an alternative, 
short-term end point to 5-year OS when assessing the efficacy 
of novel chemotherapeutic agents as adjuvants in bladder cancer 
clinical trials. In other words, the goal of prospective novel anti-
cancer drug development for advanced bladder cancer will focus 
on the improvement of DFS.
The present study is limited by several factors. First, the study’s 
retrospective, non-randomized design could not control for the 
presence of unidentified confounding factors. Our data were 
extracted from patients who underwent RC performed by multi-
ple surgeons over a 20-year period. Guideline changes in surgical 
technique (i.e., PLND template) and pathological report content 
(i.e., variant histology) represent time-dependent variables that 
FigUre 3 | hazard ratio of landmark analysis at each time point. (a) All patients. (B) Patients with pT2 or less disease. (c) Patients with pT3 or greater 
disease. Dashes indicate 95% confidence intervals.
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FigUre 4 | Five-year survival rates of patients who achieved each outcome. (a) All patients. (B) Patients with pT2 or less disease. (c) Patients with pT3 or 
greater disease. The bars indicate 95% confidence interval.
may have impacted our results. Furthermore, inter-physician 
variation based on surgery-related expertise, determination 
of adjuvant chemotherapy implementation, type of adjuvant 
chemotherapy regimen assigned, and postoperative follow-up 
strategies could affect the current study results. Although adju-
vant chemotherapy regimen was not defined in the current study, 
the strong correlation observed between DFS and OS irrespective 
of adjuvant chemotherapy indicates that the association may not 
be regimen specific. Lastly, the study population was recruited 
from a single institution and included a relatively small sample 
size; therefore, the results derived from this study should be 
further validated externally using well-designed, randomized 
clinical trials.
cOnclUsiOn
We externally validated the existing correlation between 2- and 
3-year DFS and 5-year OS in patients who underwent RC for UC 
of the bladder. In particular, our validation suggests that 2- and 
3-year DFS can be used as a potential early surrogate end point 
to predict or replace 5-year OS in future adjuvant bladder cancer 
clinical trials. Further external validation through well-designed 
prospective randomized trials will be required to confirm the role 
of DFS as the primary end point in bladder cancer.
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